FindTrial
Sign In

Artemisinin based Combination therapy Trial

A Randomized Trial of Dihydroartemisinin-piperaquine (Malacur®) versus Artemether-lumefantrine (Coartem®) for Treatment of uncomplicated Plasmodium falciparum Malaria in Mali

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201803003018369
Enrollment
Unknown
Registered
2018-01-26
Start date
2013-09-27
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malaria

Interventions

Dihydroartemisinin-piperaquine (Malacur)
Artemether-lumefantrine (AL)

Sponsors

Laboratorios SALVAT, S.A.,
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria were: older than or equal to six months, with an axillary temperature of ¿ 37°Celcius or history of fever within 24 hours prior enrollment, being resident of Doneguebougou and Torodo since six months, able to take oral treatment, a parasitemia between 1000 and 100,000 asexual Plasmodium falciparum/¿l of blood, having QTc ¿ 450 msec, to sign an informed written consent and to have not used any ACTs components within 28 days before enrollment.

Exclusion criteria

Exclusion criteria: Patients were excluded if they had symptoms or signs of severe malaria, were unable to take oral medication, had an allergy to one of the study drugs or were pregnant (detected with a urine beta-human chorionic gonadotropin test).

Design outcomes

Primary

MeasureTime frame
Adequate Clinical and Parasitological Response—

Secondary

MeasureTime frame
Anemia clearance—

Countries

Mali

Contacts

Public ContactIssaka Sagara
isagara@icermali.org0022320228109

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026